Amedisys (AMED) | Stock Overview & Key Data
Amedisys Performance Comparison
Stock Range
Today's Range
Low: $100.85
High: $100.97
on August 8, 2025
52 Week Range
Low: $82.15
High: $100.99
on December 20, 2024
on August 7, 2025
All-Time High: $325.12 on January 25, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.3B
EPS
2.57
P/E Ratio (TTM)
38.63
Forward P/E
19.43
P/B Ratio
2.65
PEG Ratio
19.43
Div. Yield
N/A
ROE
6.67%
Beta
0.901
Debt to Equity
35.34
Financial Highlights
Profitability
Gross Margin
43.96%
Operating Margin
11.70%
Profit Margin
3.56%
Returns and Earnings
Return on Assets (TTM)
6.52%
Return on Equity (TTM)
6.67%
EBITDA
$365.0M
Net Income (TTM)
$85.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$73.30
Quarterly Revenue Growth (YoY)
5.20%
Quarterly Earnings Growth (YoY)
-13.10%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Amedisys AMED | 3.27B Mid-cap | 2.47% | 3.35% | 6.03% | 9.68% | 11.05% | 3.24% | -17.52% | -56.18% |
| HCA Healthcare HCA | 89.29B Large-cap | 6.90% | 1.06% | 7.82% | 19.91% | 28.16% | 5.74% | 74.34% | 183.87% |
| Tenet Healthcare THC | 14.23B Large-cap | 4.74% | -3.95% | 11.08% | 18.74% | 32.23% | 10.34% | 147.21% | 469.39% |
| Ensign Group ENSG | 9.12B Mid-cap | 5.85% | 10.15% | 17.87% | 24.30% | 20.89% | 13.83% | 83.05% | 189.50% |
| Chemed CHE | 6.25B Mid-cap | 4.18% | -6.56% | -23.50% | -21.37% | -17.54% | -25.00% | -11.35% | -14.11% |
| Option Care Health OPCH | 4.56B Mid-cap | -0.21% | -8.59% | -11.04% | -10.05% | 24.23% | -5.50% | -18.90% | 123.10% |
Ownership & Short Interest
Insider Ownership
1.95%
Institutional Ownership
92.91%
Shares Short
2M
Short Ratio
4.66
Short % of Shares Outstanding
6.94%
Average 10-Day Volume
720K
Average 90-Day Volume
516K
Amedisys Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Amedisys would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AMED's 52-week high and low?
- In the last 52 weeks, Amedisys reached a high of $100.99 (on August 7, 2025) and a low of $82.15 (on December 20, 2024).
- What is the market cap and P/E ratio for AMED?
- Curious about Amedisys's size and valuation? Its market capitalization stands at 3.27B. When it comes to valuation, the P/E ratio (trailing twelve months) is 38.63, and the forward P/E (looking ahead) is 19.43.
- Does AMED pay dividends? If so, what's the yield?
- As for dividends, Amedisys isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Amedisys's main competitors or similar companies to consider before investing?
When looking at Amedisys, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return HCA Healthcare
HCA89.29B Healthcare Medical Care Facilities 5.74% 74.34% Tenet Healthcare
THC14.23B Healthcare Medical Care Facilities 10.34% 147.21% Ensign Group
ENSG9.12B Healthcare Medical Care Facilities 13.83% 83.05% Chemed
CHE6.25B Healthcare Medical Care Facilities -25.00% -11.35% Option Care Health
OPCH4.56B Healthcare Medical Care Facilities -5.50% -18.90% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Amedisys Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Amedisys's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 6.67%, the Debt to Equity ratio from the most recent quarter is 35.34, and its Gross Profit Margin stands at 43.96%.
- What is the recent revenue and earnings growth for AMED?
- Looking at Amedisys's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.20%, and quarterly earnings saw a YoY growth of -13.10%.
- How much of AMED stock is held by insiders and institutions?
- Wondering who owns Amedisys stock? Company insiders (like executives and directors) hold about 1.95% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 92.91%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.